

In the Claims:

This listing of claims will replace all prior versions and listings of claims in this application.

1 - 24 (Canceled).

25 (currently amended). A combination therapeutic comprising ~~a polypeptide according to claim 2~~ an isolated polypeptide encoded by a nucleic acid sequence, which encodes a polypeptide with neuronal tryptophan hydroxylase activity, wherein the nucleic acid sequence is selected from the group of:

- a) a nucleic acid sequence with the sequence depicted in SEQ ID No: 1,
- b) a nucleic acid sequence that can be deduced from a nucleic acid sequence depicted in SEQ ID No: 1 as a consequence of the degenerated genetic code,
- c) derivatives of the nucleic acid sequences depicted in SEQ ID No: 1, which encode polypeptides according to SEQ ID No: 2, which display at least 95% homology at the amino acid level, wherein the tryptophan hydroxylase activity of the polypeptides is not reduced,  
and
- d) human genomic nucleic acid sequences, which contain the gene for sn-TPH and exhibit polymorphisms

and at least one additional protein for the regulation of the serotonin metabolism, and wherein the additional protein is a peripheral tryptophan hydroxylase.

26 – 28 (cancelled).

29 (new). The combination therapeutic, according to claim 25 wherein the polypeptide has 98% homology to SEQ ID NO:2.

30 (new). The combination therapeutic, according to claim 25, where the polypeptide has SEQ ID NO:2.